Zemprocitinib maintains ACR20 response in 90% of RA patients at 76 weeks in Phase III trial, with consistent safety profile and comparable crossover rates.
Hengrui Pharma presents 64 studies at ESMO 2026, a record for the Chinese oncology company showcasing 14 approved innovative ...
Qutenza meets primary pain endpoint in post-surgical neuropathy trial, showing sustained benefit over ten months in extension ...
Atrium Therapeutics doses first patient in ATR-1072 trial for PRKAG2 syndrome, targeting the genetic cause of cardiac disease ...
Enanta dosed its first RESOLVE patient Oct 26. High-risk adult RSV outpatient capacity is already strained, here's what site ...
Cecolin 9 shows six-month immunogenicity data in single-dose HPV trial against Gardasil 9, with final results expected in ...
EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes ...
Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for ...
The MDT-BRIDGE trial's 142-patient neoadjuvant durvalumab dataset introduces a multidisciplinary reassessment architecture ...
ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial, with potential for once-yearly dosing in ...
Citius Oncology reports preliminary LYMPHIR unit sales and vial orders for Q4 2026, signaling commercial momentum in the ...
Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results